Abstract 520P
Background
Adding atezolizumab to the established etoposide and carboplatin chemotherapy (AECb) for extensive-stage small cell lung cancer (ES-SCLC) is now standard, following success of Impower 133 trial. Controlling central nervous system (CNS) progression is pivotal for patients’ survival and quality of life. We explored a role of atezolizumab in controlling brain metastasis in ES-SCLC patients.
Methods
A total of 156 patients, diagnosed with ES-SCLC and received 1st line chemotherapy between August 2016 and July 2022 at Korea University Guro Hospital, were included. Survival data, comprising progression-free survival (PFS), overall survival (OS), time to intracranial progression (TTicP, with deaths censored) and brain PFS, were evaluated.
Results
During the study period, 79 (50.6%) patients underwent chemotherapy without atezolizumab, while 77 (49.4%) patients received AECb as their initial treatment. The median follow-up duration was 23.8 months, and there were no discernible differences between two groups in terms of age, sex and primary metastatic sites. Patients in the AECb group exhibited improved CNS outcomes: 27 (34.2%) and 16 (20.8%) patients experienced intracranial progression, with 24 (30.4%) and 14 (18.2%) cases of new brain metastasis. Both TTicP (median: 14.6 months vs. not reached; 12-month TTicP rate: 65.4% vs. 84.4%, P = 0.003) and brain PFS (median: 8.2 vs. 11.7 months; 12-month brain PFS rate 30.2% vs. 48.6%, P = 0.001) were significantly prolonged in the AECb group. These findings remained consistent even after adjusting for age, initial metastatic site, and prophylactic cranial irradiation (PCI). As expected, the AECb group demonstrated favorable survival outcomes, marked by improved PFS (median: 4.4 vs. 4.6 months, P = 0.004) and OS (median: 10.2 vs. 12.6 months, P = 0.001).
Conclusions
The addition of atezolizumab to conventional chemotherapy not only enhances patients’ survival but also improves intracranial disease control, thereby extending the duration of time to intra-cranial progression. This is first real-world data supporting benefits of atezolizumab in controlling intracranial progression in SCLC patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
238P - Enfortumab-vedotin for metastatic urothelial carcinoma refractory to platinum-based chemotherapy and immune checkpoint inhibitors: A single institution experience
Presenter: Yuki Endo
Session: Poster Display
Resources:
Abstract
239P - Elevated baseline C-reactive protein is a prognostic indicator for OS in patients with metastatic non clear cell renal cell carcinoma treated with systemic therapy
Presenter: Ryuichi Mizuno
Session: Poster Display
Resources:
Abstract
240P - Efficacy and safety of first-line combination therapy with ipilimumab + nivolumab for metastatic renal cell carcinoma in a single institution in Japan
Presenter: Naoya Nagaya
Session: Poster Display
Resources:
Abstract
241P - First-line cabozantinib in metastatic renal cell carcinoma (mRCC): A real-world exploratory study from eastern India
Presenter: Tamojit Chaudhuri
Session: Poster Display
Resources:
Abstract
244P - Clinicopathologic feature and treatment outcome of metastatic non clear cell kidney cancer: A single centre experience from India
Presenter: Somnath Roy
Session: Poster Display
Resources:
Abstract
245P - The role of TGF-β in the formation of the protumor phenotype of circulating neutrophils at different stages of renal cancer
Presenter: Ilseya Myagdieva
Session: Poster Display
Resources:
Abstract
246P - Impact of renal impairment on first-line treatment in metastatic urothelial cancer
Presenter: Stephanie Wakeling
Session: Poster Display
Resources:
Abstract
247P - Adjuvant chemoradiotherapy in the management of bladder adenocarcinoma compared to multiple treatment modalities
Presenter: Othman Mohammed
Session: Poster Display
Resources:
Abstract
248P - Screening zinc homeostasis-related genes identifies metallothionein 1H (MT1H) as a potential prognostic biomarker in clear cell renal cell carcinoma (ccRCC)
Presenter: Eyad Al Masoud
Session: Poster Display
Resources:
Abstract
249P - The prognostic utility of Progestogen associated Endometrial protein (PAEP) gene expression in clear cell renal cell carcinoma (ccRCC)
Presenter: Leen Lataifeh
Session: Poster Display
Resources:
Abstract